---
title: "《业绩》南洋集团中期纯利 2,753 万元  亏转盈"
description: "南洋集团公布 6 月止六个月中期业绩，收入与其他收益 1.69 亿元，按年增加 17.5%。录得纯利 2,753 万元，相较去年同期亏损 4,374 万元，亏转盈；每股盈利 81 仙。不派息。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/254322857.md"
published_at: "2025-08-24T12:10:14.000Z"
---

# 《业绩》南洋集团中期纯利 2,753 万元  亏转盈

> 南洋集团公布 6 月止六个月中期业绩，收入与其他收益 1.69 亿元，按年增加 17.5%。录得纯利 2,753 万元，相较去年同期亏损 4,374 万元，亏转盈；每股盈利 81 仙。不派息。

南洋集团 (00212.HK) 公布 6 月止六个月中期业绩，收入与其他收益 1.69 亿元，按年增加 17.5%。录得纯利 2,753 万元，相较去年同期亏损 4,374 万元，亏转盈；每股盈利 81 仙。不派息。

### Related Stocks

- [00212.HK - 南洋集团](https://longbridge.com/zh-CN/quote/00212.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Huatai Securities Keeps Their Buy Rating on China Literature (CHLLF) | In a report released on February 13, from Huatai Securities maintained a Buy rating on China Literature, with a price ta | [Link](https://longbridge.com/zh-CN/news/275996484.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| Beijing Haizhi Technology Announces Final Offer Price | Beijing Haizhi Technology Group Co Ltd:FINAL OFFER PRICE HK$27.06 PER H SHARE UNDER GLOBAL OFFERING | [Link](https://longbridge.com/zh-CN/news/275780031.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-CN/news/276051793.md) |
| 23:43 ETDie innovativen Sicherheits- und hocheffizienten Antriebsstränge von GAC finden weltweite Anerkennung | GAC is gaining global recognition for its innovative and efficient drivetrains amidst the rapidly changing automotive in | [Link](https://longbridge.com/zh-CN/news/275994919.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。